Biokine Therapeutics Announces Issuance of European Patent covering the composition and use of novel
chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).
Biokine Therapeutics Announces Issuance of European Patent covering the composition and use of novel
chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation, and cancer (BKT130 project).